Belite Bio (Belite Bio) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Debt-to-Equity?

Belite Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Belite Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Belite Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $96.47 Mil. Belite Bio's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Belite Bio's Debt-to-Equity or its related term are showing as below:

BLTE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.02
Current: 0.01

During the past 4 years, the highest Debt-to-Equity Ratio of Belite Bio was 0.02. The lowest was 0.01. And the median was 0.02.

BLTE's Debt-to-Equity is ranked better than
99.91% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs BLTE: 0.01

Belite Bio Debt-to-Equity Historical Data

The historical data trend for Belite Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Debt-to-Equity Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.02

0.01

Belite Bio Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial							-	-	-	0.01	-

Competitive Comparison of Belite Bio's Debt-to-Equity

For the Biotechnology subindustry, Belite Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belite Bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Belite Bio's Debt-to-Equity falls into.

Belite Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Belite Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.308	+	0.578)	/	90.431
	=	0.01

Belite Bio's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	96.47
	=	0.00

Belite Bio (NAS:BLTE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Belite Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Belite Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio (Belite Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.